Endocrine Abstracts

This case report highlights an unusual side effect of hypophosphatemia linked to Abacavir; a medication commonly used in the treatment of HIV. A 36-year-old male patient was referred to the endocrine team due to persistent hypophosphatemia while receiving Abacavir for his HIV management. Extensive investigations, including assessments of calcium levels Urea and Electrolytes, parathyroid hormone (PTH), Vitamin D, serum magnesium, and serum cortisol and fibroblast growth factor 23 (FGF23), yielded normal results. Following these findings, the case was discussed in an endocrine multidisciplinary team (MDT) meeting, leading to a consensus that the hypophosphatemia was likely associated with Abacavir use. This report aims to contribute to the existing body of evidence regarding this uncommon side effect. By presenting this case, we seek to raise awareness among healthcare professionals about the potential for hypophosphatemia in individuals undergoing Abacavir treatment for HIV. The involvement of various experts in the MDT discussion adds weight to the conclusion that the observed hypophosphatemia is likely attributed to Abacavir. This case report underscores the importance of considering medication-induced complications in patients with persistent hypophosphatemia, even when routine investigations produce normal results. By sharing this clinical observation, we hope to contribute valuable information to the medical community, fostering a better understanding of potential side effects associated with Abacavir and aiding in the optimization of patient care.